Homozygous Familial Hypercholesterolemia Therapeutics
1. Juxtapid patent expiration
Treatment: Treatment of hypercholesterolemia, hyperlipidemia and hyperlipoproteinemia in patients with homozygous familial hypercholesterolemia; Treatm...
JUXTAPID's oppositions filed in EPO
JUXTAPID IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5712279 | CHIESI | Inhibitors of microsomal triglyceride transfer protein and method |
Feb, 2020
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5739135 | CHIESI | Inhibitors of microsomal triglyceride transfer protein and method |
Apr, 2015
(10 years ago) | |
| US6492365 | CHIESI | Microsomal triglyceride transfer protein |
Dec, 2019
(6 years ago) | |
| US5712279 | CHIESI | Inhibitors of microsomal triglyceride transfer protein and method |
Feb, 2015
(10 years ago) | |
| US7932268 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Aug, 2027
(1 year, 7 months from now) | |
| US8618135 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(10 months ago) | |
| US10016404 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(10 months ago) | |
| US9433617 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(10 months ago) | |
| US9265758 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(10 months ago) | |
| US9364470 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(10 months ago) | |
| US9861622 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(10 months ago) | |
| US10555938 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(10 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2019 |
| Orphan Drug Exclusivity(ODE-36) | Dec 21, 2019 |
Drugs and Companies using LOMITAPIDE MESYLATE ingredient
NCE-1 date: 21 December, 2016
Market Authorisation Date: 21 December, 2012
Dosage: CAPSULE
More Information on Dosage
JUXTAPID family patents
2. Kynamro patent expiration
Treatment: Adjunctive therapy to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol, apolipoprotein b, total cholesterol, and non-high density lipoprotein cholesterol in pts with <...
KYNAMRO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7511131 | KASTLE THERAPS LLC | Antisense modulation of apolipoprotein B expression |
Jan, 2027
(1 year, 20 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5914396 | KASTLE THERAPS LLC | 2'-O-modified nucleosides and phosphoramidites |
Jun, 2016
(9 years ago) | |
| US6222025 | KASTLE THERAPS LLC | Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom |
Mar, 2015
(10 years ago) | |
| US6166197 | KASTLE THERAPS LLC | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
Dec, 2017
(8 years ago) | |
| US7101993 | KASTLE THERAPS LLC | Oligonucleotides containing 2′-O-modified purines |
Sep, 2023
(2 years ago) | |
| US7407943 | KASTLE THERAPS LLC | Antisense modulation of apolipoprotein B expression |
Aug, 2021
(4 years ago) | |
| US7015315 | KASTLE THERAPS LLC | Gapped oligonucleotides |
Mar, 2023
(2 years ago) | |
| US6451991 | KASTLE THERAPS LLC | Sugar-modified gapped oligonucleotides |
Feb, 2017
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 29, 2018 |
| Orphan Drug Exclusivity(ODE) | Jan 29, 2020 |
| Orphan Drug Exclusivity(ODE-41) | Jan 29, 2020 |
Drugs and Companies using MIPOMERSEN SODIUM ingredient
NCE-1 date: 29 January, 2017
Market Authorisation Date: 29 January, 2013
Dosage: SOLUTION
More Information on Dosage
KYNAMRO family patents